Phacilitate Leaders Forum

17th - 18th SEPTEMBER 2019



Andreas  Weiler

Andreas Weiler

Global Business Unit Head of Emerging Technologies, Lonza

Andreas Weiler is the Global Business Unit Head of Emerging Technologies at Lonza Pharma & Biotech, where he oversees the cell and gene therapy contract manufacturing businesses. Before joining Lonza, Andreas worked for Sigma Aldrich (SAFC) for over 17 years, another leading CDMO (Contract Development and Manufacturing Organization) to the pharma/biotech industries, where he held several positions as Business Director and finally as the Head of Strategic Marketing to the organization. Since 2015, when Andreas joined Lonza, Cell and Gene Therapy sales have more than doubled and the manufacturing footprint expanded significantly to cover the globe with facilities in North America, Europe and Asia. Andreas holds a PhD in Organic Chemistry from University of Freiburg and an MBA degree.

  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Jean-Philippe Combal
    GenSight Biologics
  • The conference consistently proves to be a great forum for networking with industry leaders in the development of cellular and gene therapies as well as vendors for important technologies and services.
    Michael Covington
    Juno Therapeutics, Inc
  • It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance
    Bertrand Alexandre
  • Phacilitate EU delivered it's promise and more, the topics discussed were highly relevant, with very good and professional speakers and panelists. You will see me next year in Berlin.
    Dr Ohad Karnieli
    Karnieli Ltd